

#### Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

CIN: L24234KA1978PLC003417

#### www.biocon.com

# BIO/SECL/AJ/2023-24/132

### December 13, 2023

То,	То,
The Manager	The Manager
BSE Limited	National Stock Exchange of India Limited
Department of Corporate Services	Corporate Communication Department
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai – 400 001	Mumbai – 400 050
Scrip Code – 532523	Scrip Symbol - BIOCON

## Subject: Intimation under Regulation 30 of SEBI Listing Regulations.

Dear Sir/Madam,

Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby inform you that Bicara Therapeutics Inc. ("Bicara"), an associate company of Biocon Limited, has on December 12, 2023, completed its US\$165 Million Series C financing. The proceeds of the funding shall be used to support the continued advancement of Bicara's lead product candidate, BCA101, a first-in-class bifunctional EGFR/TGF- $\beta$  inhibitor that is currently in clinical development for multiple cancer types. The media release made by Bicara in this regard can be accessed at <a href="https://www.bicara.com/bicara-therapeutics-announces-oversubscribed-165-million-series-c-financing/">https://www.bicara.com/bicara-therapeutics-announces-oversubscribed-165-million-series-c-financing/</a>.

Consequent to this infusion of Series C funding and post allotment of shares by Bicara, the Company's shareholding in Bicara on fully diluted basis will fall below 20% and thereby, Bicara will cease to be an associate company of Biocon Limited.

The above information will also be available on the website of the Company at <u>www.biocon.com</u>.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited